REG - EKF Diagnostics Hldg - Posting of Annual Report & Accounts &Notice of AGM

EKF Diagnostics HoldingsAnnouncement

25/04/2022 07:01

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220425:nRSY1031Ja&default-theme=true

RNS Number : 1031J  EKF Diagnostics Holdings PLC  25 April 2022

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Posting of Annual Report & Accounts

and

Notice of Annual General Meeting

 

EKF (AIM: EKF), the AIM-listed global diagnostics business, confirms that
the Annual Report and Accounts for the year ended 31 December 2021 ("2021
Annual Report") and the Notice of the 2022 Annual General Meeting ("AGM") have
now been published on the Company's website here
(https://www.ekfdiagnostics.com/documents-reports.html) .

 

The 2021 Annual Report, the Notice of AGM and details for voting by
proxy will be posted to shareholders who have not consented to receive
electronic communications today, on 25 April 2022.

 

The AGM is to be held at 11:00 am on 18 May 2022 at 6 Stratton Street
Mayfair, London W1J 8LD and will consider the Resolutions set out in the
Notice of AGM.

 

The Company is providing a facility for shareholders to listen in to the AGM
either online or telephonically (in a non-voting capacity) and there will be
an opportunity for shareholders to ask questions. In order to facilitate the
process, the Directors would request that shareholders register for the
meeting and submit questions in advance, before 11:00 am on 17 May 2022. To
register for dial-in details and to submit any questions please contact
Walbrook PR via email at ekf@walbrookpr.com (mailto:ekf@walbrookpr.com) or
call +44 (0)20 7933 8787.

 

Proxy voting

Shareholders will not receive a hard copy form of proxy for the 2022 AGM in
the post. Instead, Shareholders will be able to vote electronically using the
link www.signalshares.com (http://www.signalshares.com) . Proxy votes must be
received no later than 11:00 am on 16 May 2022.

 

Shareholders may request a hard copy form of proxy directly from the
Registrars, Link Group, on Tel: 0371 664 0300. Calls are charged at the
standard geographic rate and will vary by provider. Calls outside the United
Kingdom will be charged at the applicable international rate. Lines are open
between 09:00 - 17:30, Monday to Friday excluding public holidays in England
and Wales.

 

 EKF Diagnostics Holdings plc                  www.ekfdiagnostics.com (http://www.ekfdiagnostics.com)
 Mike Salter, CEO                               Tel: +44 (0)29 2071 0570
 Marc Davies, CFO

 Singer Capital Markets (Nominated Adviser & Joint Broker)                              Tel: +44 (0)20 7496 3000
 Aubrey Powell / George Tzimas / Tom Salvesen

 Investec Bank plc (Joint Broker)              Tel: +44 (0)20 7597 4000
 Gary Clarence / Daniel Adams / Ben Farrow

 Walbrook PR Limited                           Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com (mailto:ekf@walbrookpr.com)
 Paul McManus / Lianne Applegarth              Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com
(http://www.ekfdiagnostics.com) )

EKF is a leading global diagnostics business with custom manufacturing
facilities across sites in the US, UK and Europe for a variety of life science
products. EKF is focussed on the following areas:

 

 Point-of-Care             Providing a portfolio of Point-of-Care analysers and consumables, particularly
                           for use in the area of Hematology and Diabetes, for use in hospital and
                           research laboratories, doctor's offices, blood banks and for in-field anaemia
                           screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit,
                           HbA1c, glucose and lactate analysers in regular use across more than 100
                           countries.

 Central Laboratory        Clinical chemistry, Small lab analysers, Centrifuges

                           Beta-Hydroxybutyrate (β-HB) LiquiColor, Glycated Albumin, Glycated Serum
                           Protein, Nitro-tab, Procalcitonin

 Life Sciences             Enzyme fermentation, Custom products and Bulk fermentation

 Contract Manufacturing    Bulk formulation, Sample collection kits, Private labelling, Molecular and
                           forensic kits

 Laboratory Services       In September 2021, EKF completed the acquisition of Advanced Diagnostic
                           Laboratory LLC ("ADL Health"), a Texas based testing laboratory certified
                           under the Clinical Laboratory Improvement Amendments ("CLIA") for high
                           complexity testing. The laboratory provides testing for a variety of clinical,
                           forensic and microbiological sample types using a range of analytical
                           techniques. This acquisition positions EKF as a leading 'one stop' provider of
                           diagnostic products and services from sample collection to results.

 

In May 2021, EKF announced its strategy for delivering growth to 2024 and
beyond, and continuing to deliver shareholder value. The strategy for growth
can be summarised as:

 

 •    continuing innovation in products and services in Point-of-Care, Central
      Laboratory and Life Sciences leveraging new and existing routes to market and
      relationships;
 •    investment in expanded production and kitting capabilities to offer a suite of
      diagnostic Contract Manufacturing solutions to third party businesses;
 •    expansion of CLIA Laboratories Testing offering, building on the acquired
      capabilities in ADL Health; and
 •    identify complementary earnings-enhancing acquisitions with key strategic
      value.

 

EKF will also continue to generate enhanced shareholder value through:

 

 •    a progressive dividend policy; and
 •    its agreement with Mount Sinai Innovation Partners ("MSIP"), which allows us
      advanced access to innovative commercial opportunities and where we can build
      on the ongoing successes of Renalytix plc, Verici Dx plc and Trellus Health
      plc.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACSITMITMTATBPT